Major pharmaceutical advancements in the field of inflammatory bowel diseases benefit to children and adolescents affected with this progressive chronic condition. Scientific organisations such as ESPGHAN and ECCO actively publish guidelines related to the many aspects of care from these patients. Clinical studies and long-term prospective registries in the appropriate age groups are crucial to support an evidence based strategy.

Original languageEnglish
Pages (from-to)461-464
Number of pages4
JournalImmunopharmacology and Immunotoxicology
Volume40
Issue number6
Early online date24 Jul 2018
DOIs
Publication statusPublished - Dec 2018

    Research areas

  • Inflammatory bowel disease, children, clinical studies, pediatrics, treatment

ID: 44677502